Champions Oncology 1st Annual Boston Symposium


Thursday, September 19, 2019 at Museum of Science
The d’Arbeloff Suite and Skyline Rooms
1 Science Park, Boston, MA 02114

Registration Now Open

Join industry leaders, learn about the latest research and network with colleagues. 

Choose from two tracks designed to drive your drug discovery and development programs.


Learn about Current Trends in Translational Oncology

Join Boston’s leading oncology innovators. Learn from experts about their current therapeutic approach to today’s oncology challenges. Gain insight on how to further support your oncology and immuno-oncology drug development programs, from preclinical and translational studies, to research in the clinic, by attending the Champions Oncology drug discovery symposium. 

Date and Time:

September 19th 2019, 8AM-4PM Sessions, 4PM – 5:30PM Reception

Topics Include:

  • How to use PDX models to run effective in vivo pre-clinical trials
  • Next-generation humanized mouse models for immuno-oncology
  • Novel approaches to targeting immunosuppression in cancer

Scheduled Speakers for the Translational Oncology Track:

Check back for updates to the agenda and speakers.

  • Kevin Mills, PhD, CSO, Cyteir, Inc.
  • Amy Wesa, PhD, Director, Immuno-Oncology Research, Champions Oncology, Inc.
  • Samuel Y. Ng, MD, PhD, Faculty, Dana-Farber Cancer Institute
  • Carla F. Kim, PhD, Faculty, Harvard Stem Cell Institute
  • Brandon Nicolay, PhD, Senior Scientist, Agios Pharmaceuticals, Inc.
  • Corinne Reimer, PhD, Director, In Vivo Pharmacology, AstraZeneca, Inc.
  • Henia Darr-Farrell, PhD, Senior Scientist, CRISPR Therapeutics, Inc.
  • Dennis Huszar, PhD, Senior Director, Immuno-Oncology Research, Takeda Pharmaceuticals, Inc.
  • Masood Shammas, PhD, Faculty, Dana-Farber Cancer Institute
  • Weiguo Yao, PhD, Director of Immunology, Palleon Pharmaceuticals, Inc
  • David Quinn, Scientific Lead Translational Immuno-Oncology, Novartis Institute for Biomedical Research
  • Stefanie Schalm, PhD, Principal Scientist, Blueprint Medicines, Inc.

Who Should Attend:

R&D, discovery, preclinical and translational teams from pharma, biotech, and academia


Learn about Flow Cytometry in Clinical Drug Development 

Join Boston’s leading flow cytometry experts. This interactive workshop will provide insight into the techniques to develop, validate, interpret and integrate your flow cytometry data for maximal benefit. Learn about best practices in applications of flow cytometry toward progression of drugs through clinical trials.

Date and Time:

September 19th 2019, 12-4PM Sessions, 4PM – 5:30PM Reception

Topics Include:

  • How to get the most out of your flow cytometry data
  • Regulatory approaches to flow cytometry: development and validation of high-complexity panels
  • Exploratory end-points in early stage clinical trials
  • Functional immune assessment by flow cytometry

Scheduled Speakers for the Flow Cytometry Track:

Check back for updates to the agenda and speakers.

  • Greg Bannish, PhD, Head of Flow Cytometry, Champions Oncology, Inc.
  • Nathan Hedrick, PhD,  Head of Clinical Flow Cytometry, BMS
  • David M. Dorfman, MD, PhD, Professor of Pathology, Harvard Medical School; Medical Director, Hematology Laboratory, Brigham and Women’s Hospital
  • Amy S. Duffield, MD, PhD, Associate Professor of Pathology, Division of Hematologic Pathology, Johns Hopkins University; Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Who Should Attend:

Clinical, translational, biomarker, pharmacology, drug efficacy, and safety teams from pharma, biotech, and academia